Literature DB >> 25964831

Diagnosis and treatment of patients with thyroid cancer.

Quang T Nguyen1, Eun Joo Lee2, Melinda Gingman Huang2, Young In Park2, Aashish Khullar3, Raymond A Plodkowski4.   

Abstract

BACKGROUND: Thyroid cancer is the most common malignancy of the endocrine system, representing 3.8% of all new cancer cases in the United States and is the ninth most common cancer overall. The American Cancer Society estimates that 62,450 people in the United States will be diagnosed with thyroid cancer in 2015, and 1950 deaths will result from the disease.
OBJECTIVE: To review the current approach to the diagnosis and treatment of patients with thyroid cancer. DISCUSSION: Over the past 3 decades, there has been a dramatic increase in the number of people diagnosed with thyroid cancer, which may be attributable to the wide use of imaging studies, including ultrasounds, computed tomography, magnetic resonance imaging, and positron emission tomography scans that incidentally detect thyroid nodules. Thyroid cancer is divided into several main types, with papillary thyroid cancer being the most common. The treatment options for patients with thyroid cancer include the surgical removal of the entire thyroid gland (total thyroidectomy), radioactive iodine therapy, and molecular-targeted therapies with tyrosine kinase inhibitors. This article summarizes the diagnosis and treatment of thyroid cancer, with recommendations from the American Thyroid Association regarding thyroid nodules and differentiated thyroid cancer. Recently approved drugs and treatment trends are also explored.
CONCLUSION: The prognosis and treatment of thyroid cancer depend on the tumor type and its stage at the time of diagnosis. Many thyroid cancers remain stable, microscopic, and indolent. The increasing treatment options for patients with thyroid cancer, including therapies that were recently approved by the US Food and Drug Administration, have kept the mortality rate from this malignancy low, despite the increase in its incidence. Early diagnosis and appropriate treatment can improve prognosis and reduce mortality.

Entities:  

Keywords:  endocrine system; fine-needle aspiration biopsy; radioactive iodine; thyroid cancer; thyroidectomy; tyrosine kinase inhibitors

Year:  2015        PMID: 25964831      PMCID: PMC4415174     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  37 in total

1.  Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Authors:  Maria E Cabanillas; Steven G Waguespack; Yulia Bronstein; Michelle D Williams; Lei Feng; Mike Hernandez; Adriana Lopez; Steven I Sherman; Naifa L Busaidy
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

Review 2.  Diagnosis and treatment of patients with thyroid cancer.

Authors:  Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2015-02

3.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

Authors:  Martin Schlumberger; Bogdan Catargi; Isabelle Borget; Désirée Deandreis; Slimane Zerdoud; Boumédiène Bridji; Stéphane Bardet; Laurence Leenhardt; Delphine Bastie; Claire Schvartz; Pierre Vera; Olivier Morel; Danielle Benisvy; Claire Bournaud; Françoise Bonichon; Catherine Dejax; Marie-Elisabeth Toubert; Sophie Leboulleux; Marcel Ricard; Ellen Benhamou
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

Review 4.  Thyroid nodules.

Authors:  Mary Jo Welker; Diane Orlov
Journal:  Am Fam Physician       Date:  2003-02-01       Impact factor: 3.292

5.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.

Authors:  G Riesco-Eizaguirre; P Gutiérrez-Martínez; M A García-Cabezas; M Nistal; P Santisteban
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

6.  Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer.

Authors:  F Vaisman; A Shaha; S Fish; R Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2011-07       Impact factor: 3.478

7.  BRAF mutation in papillary thyroid carcinoma.

Authors:  Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky
Journal:  J Natl Cancer Inst       Date:  2003-04-16       Impact factor: 13.506

8.  Attributable costs of differentiated thyroid cancer in the elderly Medicare population.

Authors:  Melissa M Boltz; Christopher S Hollenbeak; Eric Schaefer; David Goldenberg; Brian D Saunders
Journal:  Surgery       Date:  2013-08-22       Impact factor: 3.982

9.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

Authors:  Samuel A Wells; Bruce G Robinson; Robert F Gagel; Henning Dralle; James A Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; James R Vasselli; Jessica Read; Peter Langmuir; Anderson J Ryan; Martin J Schlumberger
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

10.  Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.

Authors:  H Tala; R Robbins; J A Fagin; S M Larson; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2011-05-11       Impact factor: 5.958

View more
  77 in total

1.  EZH2 Overexpression as a Useful Prognostic Marker for Aggressive Behaviour in Thyroid Cancer.

Authors:  Katsuhiko Masudo; Nobuyasu Suganuma; Hirotaka Nakayama; Takashi Oshima; Yasushi Rino; Hiroyuki Iwasaki; Kenichi Matsuzu; Kiminori Sugino; Koichi Ito; Tetsuo Kondo; Yoshiyasu Nakamura; Mitsuyo Yoshihara; Munetaka Masuda; Yohei Miyagi
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 2.  Imaging of intranasal drug delivery to the brain.

Authors:  Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

3.  Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas.

Authors:  Mojdeh Mahdiannasser; Vahid Haghpanah; Elia Damavandi; Majid Kabuli; Seyed Mohammad Tavangar; Bagher Larijani; Mohsen Ghadami
Journal:  Mol Biol Rep       Date:  2020-02-18       Impact factor: 2.316

4.  A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.

Authors:  Carolina Pires; Inês Jorge Marques; Daniela Dias; Ana Saramago; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2021-03-08       Impact factor: 3.633

Review 5.  Diagnosis and treatment of patients with thyroid cancer.

Authors:  Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2015-02

6.  Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-Up.

Authors:  Amblessed E Onuma; Eliza W Beal; Fadi Nabhan; Tasha Hughes; William B Farrar; John Phay; Matthew D Ringel; Richard T Kloos; Lawrence A Shirley
Journal:  Ann Surg Oncol       Date:  2019-02-28       Impact factor: 5.344

7.  LncRNA XIST Promotes Migration and Invasion of Papillary Thyroid Cancer Cell by Modulating MiR-101-3p/CLDN1 Axis.

Authors:  Yong-Liang Du; Yan Liang; Yan Cao; Le Liu; Jian Li; Guang-Qing Shi
Journal:  Biochem Genet       Date:  2020-10-14       Impact factor: 1.890

Review 8.  Importance of cost-effectiveness and value in cancer care and healthcare policy.

Authors:  Ravinder Kang; Philip P Goodney; Sandra L Wong
Journal:  J Surg Oncol       Date:  2016-06-22       Impact factor: 3.454

9.  Thyroid Cancer Epidemiology in South Spain: a population-based time trend study.

Authors:  Elena Salamanca-Fernández; Miguel Rodriguez-Barranco; Yoe-Ling Chang-Chan; Daniel Redondo-Sánchez; Santiago Domínguez-López; Eloísa Bayo; Dariusz Narankiewicz; José Expósito; María José Sánchez
Journal:  Endocrine       Date:  2018-07-24       Impact factor: 3.633

10.  Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.

Authors:  Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista M D La Perle; Laura Boucai; Lawrence S Kirschner
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.